FDA approves Gadavist (gadobutrol) for central nervous system imaging scans

The U.S. Food and Drug Administration has approved Gadavist (gadobutrol), a gadolinium-based contrast agent, for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system.

Gadavist provides contrast-enhanced imaging of the central nervous system, helping to detect and visualize lesions that disrupt the cell barrier that normally separates the brain from the blood stream. It also helps to detect and visualize abnormal blood supply and circulation of the central nervous system.

" Gadavist MRI scans improved the visualization of lesions in the central nervous system when compared to MRI scans without contrast," said Libero Marzella, M.D., acting division director, Division of Medical Imaging Products in the FDA's Center for Drug Evaluation and Research.

Gadavist is the sixth gadolinium-based contrast agent (GBCA) approved by the FDA for use in patients undergoing magnetic resonance imaging of the central nervous system. It is indicated for adults and children ages 2 years and older. Gadavist is more concentrated than the other GBCAs and should be administered at half the volume. Two clinical studies involving 657 patients and other trial data established the safety and efficacy of Gadavist.

All GBCAs, including Gadavist, carry a boxed warning about the risk of nephrogenic systemic fibrosis (NSF), a rare, but serious, condition associated with the use of GBCAs in certain patients with kidney dysfunction. NSF is characterized by pain and thickening of the skin, and can cause fibrosis of internal organs. There is no known treatment for NSF. Gadavist is currently considered to be one the GBCAs with a lower risk of NSF, and is not one of the GBCAs that is contraindicated in patients with acute kidney injury or chronic, severe kidney disease.

Those receiving Gadavist during the studies reported headache and nausea as the most common adverse reactions. Other adverse events associated with Gadavist included hypersensitivity reactions, involving cardiovascular, respiratory, or skin effects ranging from mild to severe.

Gadavist is manufactured by Bayer Pharmaceuticals, Wayne, N.J.

News is included on the IvyRose website to inform visitors about current health and related issues, but not to endorse any particular view or activity. Any views expressed in the article above are not necessarily those of IvyRose Ltd.. Material in this news item was released by the United States (U.S.) Food and Drug Administration (FDA) on 14 March 2011 . It may have been edited (e.g. in style, length, and/or for ease of understanding by our international readers) for inclusion here. For further information, please visit their website.

Please send any medical or health news press releases to: pressrelease@ivyrose.co.uk.